通过稳定低密度脂蛋白受体而降低低密度脂蛋白胆固醇,并防止动脉硬化
Jin-Kai Wang1, Yang Li2, Xiao-Lu Zhao1
1Institute for Advanced Studies, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, TaiKang Center for Life and Medical Sciences, TaiKang Medical School, Wuhan University, China (J.-K.W., X.-L.Z., Y.-B.L., J.T., Y.-Y.X., Y. Liu, Y.W., X.-J.S., X.-Y.L., B.-L.S., J.L.).
Circulation
|February 22, 2022
概括
通过降低LDL受体 (LDLR) 来降低LDL胆固醇. 抑制PK会增加LDLR,降低胆固醇,并预防动脉样硬化,从而确定PK作为治疗点.
科学领域:
- 生物化学
- 心血管科学
- 遗传学
背景情况:
- 血中的高胆固醇会加快动脉样硬化, 这是一个长达数十年的无症状过程.
- 动脉硬化斑块破裂导致血栓形成,导致心肌梗塞或中风.
- 降低胆固醇对于预防动脉样硬化心血管疾病至关重要.
研究的目的:
- 确定与低密度脂蛋白受体 (LDLR) 结合的蛋白质.
- 在调节胆固醇水平和动脉样硬化的过程中研究Pekallikrein (PK).
- 评估PK作为心血管疾病的潜在治疗点.
主要方法:
- 通过使用LDLR作为诱,确定PK为LDLR结合蛋白.
- 分析了人体血清PK与脂质水平之间的相关性.
- 在动物模型中利用基因删除和击败PK (大鼠,小鼠,大鼠).
- 评估了PK抑制和抗PK抗体对脂质水平和动脉样硬化的影响.
- 产生了PK和Apolipoprotein的双击小鼠,以研究动脉样硬化的进展.
主要成果:
- 直接与LDLR结合,促进其溶酶体降解.
- 血清PK度与LDL胆固醇水平呈正相关性.
- 在动物中,PK遗传衰竭会增加肝脏的LDLR并降低循环中的胆固醇.
- 包括中和抗体在内的PK抑制通过升高肝脏LDLR来降低血脂质.
- 在小鼠中,PK缺乏会减缓动脉样硬化的进展.
结论:
- 通过诱导LDLR降解来调节循环中的胆固醇.
- 通过PK切除可稳定LDLR,降低LDL胆固醇,并防止动脉样硬化斑块的形成.
- 在治疗动脉样硬化心血管疾病方面,PK是一种有前途的治疗点.
相关概念视频
Atherosclerosis III: Management
56
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Atherosclerosis I: Introduction
145
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
145
Inflammation
55.9K
Overview
55.9K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
929
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
929
Cholesterol: Significance and Regulation
727
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
727
Coronary Artery Disease IV: Preventive Measures
142
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
142


